Christopher Diehl, PharmD, MBA, BCACP, clinical pharmacist, Excellus BlueCross BlueShield, discusses how the role of pharmacists has evolved with presence of value-based models and how pharmacists can ensure these value-based models succeed.
Christopher Diehl, PharmD, MBA, BCACP, clinical pharmacist, Excellus BlueCross BlueShield, discusses how the role of pharmacists has evolved with presence of value-based models and how pharmacists can ensure these value-based models succeed.
Transcript
How has the role of pharmacists evolved with the growing presence of accountable care organizations (ACOs) and value-based models?
So, they’ve really expanded their roles. Now that we’re entering these formal agreements with health systems, pharmacists are now being able to integrate directly into physicians’ offices, and they play a much bigger role. Since we’re holding them accountable for costs, for quality, pharmacists are really in a prime position to help patients succeed, help the agreements succeed, and help their health system succeed.
So, as we get further along in these agreements, we start small. We might work with 1 or 2 pharmacists that are hired to help control costs. But as they’re starting to see the value, it’s not becoming much more systemic—they want to hire more pharmacists. They see the value, they see what they can do besides just changing medications. They help with adherence, they help with cost questions. They really help fill some of the needs that a physician has given their work load.
With value-based models, how can pharmacists help ensure that medications are used optimally?
Pharmacists—they know medication, they know the ins and outs, they are able to understand insurance, they can have better conversations with patients. It’s their job, and so, now that they’re really able to use these skills through our ACO agreements, they can really start to shine. They can show the value that they bring, where it’s not just dispensing drugs. It’s not just handing them out to patients. It’s making sure they’re able to take it, that they’re able to tolerate it, that they can afford it. And, addressing any barriers that come up. It starts off small where we address simple issues. But it makes a difference. It saves patients’ lives if they’re taking their medications like they’re supposed to, and they’ll have better health outcomes because of it.
How does this, in turn, ensure that value-based models succeed?
By doing what’s right. By addressing all the patient barriers by making sure that they’re able to take cost-effective medications, that they can afford it. We’re able to see long-term health outcomes. They’re avoiding those inpatient admissions, they’re avoiding those potential heart attacks, those other crises that happen when patients don’t take their medication. By working directly in the office beyond the capacity of working in a pharmacy, they’re able to have those relations with patients that establish that trust and really drive change.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More